Biomarkers and translational research and precision medicine

12P - Ductal carcinoma in situ of the breast: Immune cell composition according to subtype

Authors
  • Marie Colombe Agahozo (Rotterdam, Netherlands)
  • Mieke R. Van Bockstal (Woluwe-Saint-Lambert, Belgium)
  • Floris H. Groenendijk (Rotterdam, Netherlands)
  • Thierry P. Van den Bosch (Rotterdam, Netherlands)
  • Pieter Westenend (No City Provided, Namibia)
  • Carolien H. Van Deurzen (Rotterdam, Netherlands)
Speakers
  • Marie Colombe Agahozo (Rotterdam, Netherlands)

Previous ePoster
11P - Mammographic density change and risk of breast cancer

Next ePosters
14P - Outcomes of women at high familial risk for breast cancer in Australia: An 8-year single-centre experience
15P - Influence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: Pooled analysis of 484 patients from three prospective multicentre GBG trials
16P - Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer
17P - Are single hormone receptor-positive phenotypes biologically and clinically distinct breast cancer? A population-based study
18P - Secondary mechanisms of anti-HER2 resistance in breast cancer: NF1 as an actionable target
19P - The clinical impact of substituting multigene assays: Comparative clinical analysis of PAM50-ROR versus 21-gene assay
20P - ERBB2 mRNA as predictor of response to anti-HER2 antibody-drug conjugates (ADC) in breast cancer (BC)
25P - Expression of ER, PR, HER2 and Ki67 in the neoadjuvant GeparX trial: Comparison of central immunohistochemistry with an automated cartridge-based system for mRNA assessment (on behalf of the GBG neoadjuvant and translational subboard)
30P - Update on the phase II SUMMIT trial: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer
33P - Germline PALB2 heterozygous mutations in breast cancers: Haploinsufficiency paradigm